Aquestive Therapeutics (AQST) Capital Leases (2023 - 2025)
Historic Capital Leases for Aquestive Therapeutics (AQST) over the last 3 years, with Q3 2025 value amounting to $122000.0.
- Aquestive Therapeutics' Capital Leases fell 2026.14% to $122000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $122000.0, marking a year-over-year decrease of 2026.14%. This contributed to the annual value of $146000.0 for FY2024, which is 1560.69% down from last year.
- Per Aquestive Therapeutics' latest filing, its Capital Leases stood at $122000.0 for Q3 2025, which was down 2026.14% from $130000.0 recorded in Q2 2025.
- Over the past 5 years, Aquestive Therapeutics' Capital Leases peaked at $173000.0 during Q4 2023, and registered a low of $122000.0 during Q3 2025.
- In the last 3 years, Aquestive Therapeutics' Capital Leases had a median value of $149500.0 in 2024 and averaged $148625.0.
- Its Capital Leases has fluctuated over the past 5 years, first tumbled by 1560.69% in 2024, then tumbled by 2026.14% in 2025.
- Quarter analysis of 3 years shows Aquestive Therapeutics' Capital Leases stood at $173000.0 in 2023, then decreased by 15.61% to $146000.0 in 2024, then fell by 16.44% to $122000.0 in 2025.
- Its last three reported values are $122000.0 in Q3 2025, $130000.0 for Q2 2025, and $138000.0 during Q1 2025.